Skip to main content

Advertisement

Table 4 Exacerbations and hospitalizations

From: Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic hypercapnic respiratory failure: a randomized trial

VariablePatients treated with AVAPSControl groupTreatment Effect (95% CI)
6 months–baseline
P-value
6 months before inclusionStudy period
(6 months after AVAPS start)
6 months before inclusionStudy period (6 months after BiPAP start)
Exacerbation (n)2.7 ± 1.71.5 ± 0.32.6 ± 1.91.5 ± 0.2−0.9 (− 0.9 to 0.7)0.213
Hospitalization (n)3.2 ± 1.11.1 ± 0.13.5 ± 1.31.2 ± 0.1−0.1 (− 0.6 to 0.4)0.342
Hospital days(n)5.2 ± 2.13.4 ± 2.15.3 ± 2.23.5 ± 2− 1.5 (− 5 to 2)0.321
  1. number of exacerbations, hospitalizations and hospital days data